Literature DB >> 8844279

Analysis of histological heterogeneity in renal cell carcinoma: tumor size-related histological change and its prognostic significance.

H Kanamaru1, K Muranaka, H Mori, H Akino, Y Arai, K Okada.   

Abstract

BACKGROUND: It is well recognized that the histology of renal cell carcinoma (RCC) is often heterogeneous. It is also believed that the prognosis of patients with large tumors is generally poorer than those with small tumors. However, there has been no detailed study on changes in histological features of RCCs associated with tumor growth. This study was conducted to investigate whether there are any specific histological changes related to tumor size and to study the prognostic value of histological parameters in RCCs.
METHODS: The presence or absence of each histological component (3 cell types and 5 histological architectures) was investigated in 110 RCCs. The tumor size-associated changes in the histological composition of the RCCs were evaluated, and the prognostic significance of the histological parameters was analyzed using univariate and multivariate analysis.
RESULTS: The percentage of RCCs with multiple cell types increased with tumor size, whereas increases in multiplicity were not as prominent in the histological architectures. Several characteristic changes, however, were observed in both cell types and architectures. RCCs with a pure clear cell, pure alveolar pattern or cystic architectural pattern decreased, while those with granular or spindle/pleomorphic cell types, or papillary or solid architectural patterns increased with tumor size. A univariate analysis revealed that a clear cell type and an alveolar or cystic architectural pattern were associated with a better prognosis, while spindle/pleomorphic cells and a solid architecture pattern correlated with a poorer prognosis. Multivariate analysis of cell types and architectures showed, however, that only the presence of spindle/pleomorphic cell types and a solid architecture were independent prognostic variables.
CONCLUSION: The histological composition of RCCs varied according to the size of the tumor. Sarcomatous components increased with tumor size and were independently associated with a poor prognosis. Further study is warranted to correlate specific genetic alterations with tumor growth-related histological changes in RCCs.

Entities:  

Mesh:

Year:  1996        PMID: 8844279     DOI: 10.1111/j.1442-2042.1996.tb00530.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

Review 1.  Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.

Authors:  Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2019-04-28

2.  Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome.

Authors:  U Zimmermann; C Woenckhaus; S Pietschmann; H Junker; S Maile; K Schultz; C Protzel; J Giebel
Journal:  Virchows Arch       Date:  2004-08-26       Impact factor: 4.064

3.  The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion.

Authors:  Ariosto S Silva; Jose A Yunes; Robert J Gillies; Robert A Gatenby
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Adaptive therapy.

Authors:  Robert A Gatenby; Ariosto S Silva; Robert J Gillies; B Roy Frieden
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

5.  Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma.

Authors:  J Wu; G Caliendo; X P Hu; J P Dutcher
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

6.  Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma.

Authors:  N Bharwani; M E Miquel; T Powles; P Dilks; A Shawyer; A Sahdev; P D Wilson; S Chowdhury; D M Berney; A G Rockall
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.